KIEV, Ukraine & COPENHAGEN, Denmark--(BUSINESS WIRE)--Enamine Ltd., a chemical company, producer of building blocks and
screening libraries, and Danish biotech company Pcovery, have announced
that they have extended their collaboration for the discovery of new
drugs for the treatment of invasive fungal infections and platform
technology development.

“We are delighted to continue our collaboration with Pcovery and advance
to the company’s next level”

Since 2014, Enamine’s role has gradually evolved from a hit-finding
library provider to a trusted partner in the field of broadly applicable
chemistry services. A rigorous evaluation and selection process carried
out at Pcovery identified Enamine as a reliable partner that provides
state-of-the-art chemistry solutions at any level from synthesis of
small compound libraries and singletons, through route scouting and
process optimisation as well as scale-up of leads.

Under the terms of the collaboration, Pcovery’s dedicated full time
equivalent (FTE) team benefit from instant access to Enamine’s inventory
of building blocks, a collection that has been recognised for its
impeccable structural quality and significant innovative components. All
project reagent costs are covered by the FTE rate in place. While
Enamine’s experts actively participate in new composition of matter
generation, the IP produced in the collaboration solely belongs to
Pcovery.

Asked about the collaboration, William Dalby-Brown, Chief Operator
Officer at Pcovery commented: “With a plethora of CROs in the market,
finding the right partner remains a challenge. Headcount is not
everything; chemists’ skills, creativity, experience and access to the
impressive stock of contemporary building blocks were the most important
factors that ultimately led us to choose Enamine. Their remarkable work
in synthesising their collection of building blocks now helps us to
accelerate our drug discovery projects. We can pick from their stock
building blocks, whereas sourcing in other ways would incur both time
and cost. Our strategic partner Enamine is demonstrating a key role in
Pcovery’s successful path towards discovery and development of novel
anti-infective drug candidates, with a particularly strong potential for
the formation of a defensive IP position.”

“We are delighted to continue our collaboration with Pcovery and advance
to the company’s next level,” added Michael Bossert, Head of Strategic
Alliances at Enamine, continuing: “First recognition of our expertise
came with our offering of library synthesis using our end-capping
building blocks and scaffolds received from a CRO that had been working
with Pcovery previously. A relationship built on trust was rapidly
established with Pcovery, who was further convinced via our high level
chemistry service, seamless collaboration communication and positive
work environment stimulating fruitful ideas. This collaboration is
another validation of Enamine cost effective benefit for early drug
discovery activities.”